150 related articles for article (PubMed ID: 38218041)
21. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.
Mohanty SK; Smith SC; Chang E; Luthringer DJ; Gown AM; Aron M; Amin MB
Am J Clin Pathol; 2014 Aug; 142(2):173-83. PubMed ID: 25015857
[TBL] [Abstract][Full Text] [Related]
23. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
McCluggage WG; Shah R; Connolly LE; McBride HA
Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
[TBL] [Abstract][Full Text] [Related]
24. High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer.
Varma M; Morgan M; Amin MB; Wozniak S; Jasani B
Histopathology; 2003 Feb; 42(2):167-72. PubMed ID: 12558749
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.
Mhawech P; Uchida T; Pelte MF
Hum Pathol; 2002 Nov; 33(11):1136-40. PubMed ID: 12454820
[TBL] [Abstract][Full Text] [Related]
26. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
27. Prostatic adenocarcinoma with urothelial (transitional cell) carcinoma features.
Mai KT; Collins JP; Veinot JP
Appl Immunohistochem Mol Morphol; 2002 Sep; 10(3):231-6. PubMed ID: 12373149
[TBL] [Abstract][Full Text] [Related]
28. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.
Parker DC; Folpe AL; Bell J; Oliva E; Young RH; Cohen C; Amin MB
Am J Surg Pathol; 2003 Jan; 27(1):1-10. PubMed ID: 12502922
[TBL] [Abstract][Full Text] [Related]
29. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
30. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
[TBL] [Abstract][Full Text] [Related]
31. Urothelial tumors with villous morphology: Histomorphology and role of immunohistochemistry in diagnosis.
Mitra S; Chatterjee D; Das A; Gupta K; Radotra BD; Mandal AK
APMIS; 2018 Mar; 126(3):191-200. PubMed ID: 29399882
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.
Paner GP; Annaiah C; Gulmann C; Rao P; Ro JY; Hansel DE; Shen SS; Lopez-Beltran A; Aron M; Luthringer DJ; De Peralta-Venturina M; Cho Y; Amin MB
Hum Pathol; 2014 Jul; 45(7):1473-82. PubMed ID: 24780825
[TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series.
Gopalan A; Al-Ahmadie H; Chen YB; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Fine SW
Histopathology; 2022 Aug; 81(2):246-254. PubMed ID: 35758203
[TBL] [Abstract][Full Text] [Related]
34. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer.
Yang XJ; Lecksell K; Gaudin P; Epstein JI
Am J Surg Pathol; 1999 Feb; 23(2):147-52. PubMed ID: 9989840
[TBL] [Abstract][Full Text] [Related]
35. [Value of cytokeratin 7 and 20 for the diagnosis of cerebral metastases of adenocarcinoma: study of 78 cases].
Fernandez C; Liprandi A; Bouvier-Labit C; Figarella-Branger D
Ann Pathol; 2001 Apr; 21(2):129-35. PubMed ID: 11373582
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases.
Bell PD; Huber AR; Agostini-Vulaj D
Diagn Pathol; 2021 Apr; 16(1):35. PubMed ID: 33892760
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
38. TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?
Bachert SE; Di J; Zhang S; Short HE; Piecoro DW; McDonald RJ; Myint ZW; Hensley PJ; Allison DB
Hum Pathol; 2024 Jan; 143():42-49. PubMed ID: 38052269
[TBL] [Abstract][Full Text] [Related]
39. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
Samaratunga H; Khoo K
Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
[TBL] [Abstract][Full Text] [Related]
40. Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature.
Knez VM; Barrow W; Lucia MS; Wilson S; La Rosa FG
J Med Case Rep; 2014 Aug; 8():275. PubMed ID: 25124389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
